Market Intelligence, Clinical Progress, and High-Purity Reagents for Pain, Oncology, and Cardiovascular Indication Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for TRPV2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TRPV2 Recombinant Extracellular Loop Protein. Custom design available. Sequence Verified. High Purity (>95%). Endotoxin <1 EU/µg. | View TRPV2 Products |
| Gene Delivery | TRPV2 Promise-ORF / Lentivirus. Full-length ORF for stable cell lines. HEK293 Expressed. Native glycosylation preserved. Essential for multi-pass ion channel conformation. | View TRPV2 Products |
| Benchmark Ab | Anti-TRPV2 Reference Antibody. Recombinant monoclonal positive control for western blot, FACS, and immunofluorescence. Sequence Verified. | View TRPV2 Products |
| Validator | TRPV2 siRNA Set (3 unique sequences). For knockdown verification and specificity checks in functional assays. >85% knockdown guarantee. | View TRPV2 Products |
| Related Target A | TRPV1. Vanilloid subfamily homology; essential for selectivity counter-screening. Critical subfamily counter-target to validate selectivity and avoid on-target toxicity (hyperthermia). | View TRPV1 Products |
| Related Target B | TRPA1. Co-expressed mechanosensory channel; combination target for chronic pain and inflammation. Synergistic pain pathway target. | View TRPA1 Products |
| Related Target C | TRPV4. Subfamily counter-screening essential. | View TRPV4 Products |
Critical Assay Challenges & Technical Specifications
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Native Tetrameric Conformation Preservation | Lentivirus-based stable cell lines expressing full-length TRPV2 in HEK293. Maintains native stoichiometry for calcium flux and patch-clamp assays. |
| Subfamily Selectivity (TRPV1/3/4 off-target) | Comprehensive Promise-ORF and lentivirus panels for related TRP channels to verify strict selectivity. Homolog panel proteins and ortholog cell lines strictly verified by sequencing. |
| Cross-species Cyno / Mouse Evaluation | Human / Mouse / Cyno TRPV2 ortholog lentivirus particles available. Sequence Verified for preclinical translation. |
| Lack of Specificity Controls | Validated siRNA included for knockdown specificity checks. Benchmark recombinant antibodies as assay positive controls. Sequence Verified recombinant benchmark antibodies included for baseline normalization. |
| Functional Validation (Calcium Flux) | HEK293-TRPV2 Stable Cell Line ready for Fluo-4/8 assays. |
| Selectivity Mutant Studies | Pore mutant recombinant proteins available for mechanism validation (e.g., Y625A equivalent). |
Live TRPV2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TRPV2 therapeutics is intensifying. Historically overshadowed by TRPV1, TRPV2 is emerging as a critical mechanosensitive and lipid-gated ion channel involved in dilated cardiomyopathy, aggressive solid tumors (such as glioblastoma and prostate cancer), and neuroinflammation. As first-generation small molecules validate the biology, the next wave of R&D is focused on highly selective antagonists and novel modulators to treat refractory pain and tumor progression without the thermoregulatory liabilities of TRPV1 inhibitors. Known polymorphisms in dbSNP (rs3813768, rs8071215) have been identified (UniProt Q9Y5S1), providing potential pharmacogenomic markers for personalized TRPV2-targeted therapies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Antagonists | Early-stage Biotechs, Academic Consortia, Ion Channel Biotechs | Neuropathic Pain, Chronic Pain, Prostate Cancer Metastasis, Glioblastoma | Selectivity Assay (Need TRPV1/2/3/4 Lentivirus panels for cell screening) |
| Small Molecule Agonists | Cardiovascular focused Biotechs | Dilated Cardiomyopathy | Functional Activation (Need stable cell lines for Calcium Flux) |
| Biologics (mAb/ScFv) | Emerging Biotech | Inflammatory Pain, Immunology | Extracellular Loop Binding (Need native conformation Lentivirus for cell surface binding and internalization) |
| Targeted Protein Degraders / PROTACs | Emerging Platforms | Solid Tumors | Degradation Validation (Need specific knockdown controls and benchmark Abs) |
| Gene Silencing | Research Institutes | Cardiovascular Disease | Validated siRNA for knockdown verification. |
Key Genetic Variants
TarMart provides sequence-verified reagents for studying known TRPV2 polymorphisms:
- dbSNP rs3813768 (UniProt VAR_024678)
- dbSNP rs8071215 (UniProt VAR_059838)
These variants can be incorporated into custom recombinant protein or lentivirus products to support pharmacogenomic and functional studies.